AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7714974 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 micrograms)
Number of subjects: 105
Study 7714974 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (300 micrograms)
Number of subjects: 105
Study 7714974 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (400 micrograms)
Number of subjects: 105
Study 2495910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rtPA (total dose, 100 mg over 3 h)
Number of subjects: 5011
Study 699627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg) twice daily
Number of subjects: 51
Study 699627 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene (65 mg) plus paracetamol (650 mg) 3-times daily
Number of subjects: 51
Study 30992006 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP success
Number of subjects: 125
Study 30992006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar body count
Number of subjects: 125
Study 30992006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 125
Study 30992006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar body count and gestational age interaction
Number of subjects: 125
Study 28562271 — intervention group
Group type: EXPERIMENTAL
Intervention: Child care health consultation
Number of subjects: 2018
Study 28562271 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of director's experience
Number of subjects: 2018
Study 28562271 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers (e.g., lack of knowing what to do in the event of pandemic influenza)
Number of subjects: 2018
Study 28562271 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete actions taken by directors to prepare their centers
Number of subjects: 2018
Study 28562271 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience as a center director during the 2009 influenza pandemic
Number of subjects: 2018
Study 26999839 — intervention group
Group type: EXPERIMENTAL
Intervention: ABNS+SS (Allergen Blocking Nasal Spray + Seawater Spray)
Number of subjects: 60
Study 26999839 — intervention group
Group type: COMPARATOR
Intervention: SS (Seawater Spray)
Number of subjects: 60
Study 23501702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART; high Go low No‐Go)
Number of subjects: 0
Study 23501702 — intervention group
Group type: COMPARATOR
Intervention: Traditional formatted vigilance task (TFT; high No‐Go low Go)
Number of subjects: 0
Study 23501702 — intervention group
Group type: EXPERIMENTAL
Intervention: SART (random or fixed ordered)
Number of subjects: 0
Study 23501702 — intervention group
Group type: COMPARATOR
Intervention: TFT (random or fixed ordered)
Number of subjects: 0
Study 21620927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) mouthwash (Periogard)
Number of subjects: 39
Study 21620927 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (control)
Number of subjects: 39
Study 19568030 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable surface balance training (air-filled rubber disks, 5 weeks, thrice weekly sessions)
Number of subjects: 19
Study 19568030 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 16814397 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 25
Study 16814397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 14653285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel
Number of subjects: 60
Study 14653285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐Etch AB 35% phosphoric acid gel with cetylpyridinium chloride antimicrobial agent
Number of subjects: 60
Study 14653285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel followed by Concepsis chlorhexidine gluconate antimicrobial solution
Number of subjects: 60
Study 14653285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel followed by Consepsis Scrub chlorhexidine gluconate antimicrobial slurry
Number of subjects: 60
Study 14653285 — intervention group
Group type: EXPERIMENTAL
Intervention: No etchant and/or cavity pre‐treatment
Number of subjects: 60
Study 11129093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg/day) administered from day 15 to day 18
Number of subjects: 13
Study 8761192 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet on arthritis
Number of subjects: 0
Study 8761192 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet plus instruction from a health professional
Number of subjects: 0
Study 8761192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no other intervention)
Number of subjects: 0
Study 8761192 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 0
Study 1565116 — intervention group
Group type: COMPARATOR
Intervention: Lateral tilting at various angles (0 degrees, 4 degrees, 8 degrees, 12 degrees, 16 degrees, and 20 degrees)
Number of subjects: 8
Study 1565116 — intervention group
Group type: COMPARATOR
Intervention: Control position (0 degrees)
Number of subjects: 8
Study 3890229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline (300 mg bid for 7 days)
Number of subjects: 532
Study 3890229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 3890229 — intervention group
Group type: EXPERIMENTAL
Intervention: C. trachomatis presence
Number of subjects: 532
Study 3890229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect
Number of subjects: 532
Study 3890229 — intervention group
Group type: EXPERIMENTAL
Intervention: M. hominis presence, history of pelvic inflammatory disease, maternal age, gestational age, number of births, spontaneous and induced abortion, Hegar number
Number of subjects: 532
Study 29729278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study 26433040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg orally 1 hour before general anesthesia
Number of subjects: 40
Study 26433040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24789332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound scans and Doppler flow studies (intensive group)
Number of subjects: 1134
Study 24789332 — intervention group
Group type: COMPARATOR
Intervention: Single ultrasound scan at 18 weeks' gestation (control group)
Number of subjects: 1134
Study 22189527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily)
Number of subjects: 420
Study 22189527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22189527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 420
Study 19482522 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain
Number of subjects: 168
Study 19482522 — intervention group
Group type: COMPARATOR
Intervention: Non-suction drain
Number of subjects: 168
Study 18601757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A)
Number of subjects: 52
Study 18601757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B)
Number of subjects: 52
Study 15327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal lobectomy (TL)
Number of subjects: 45
Study 15327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal lobectomy (TL)
Number of subjects: 45
Study 15327933 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobectomy (TL) patients (both left and right)
Number of subjects: 45
Study 15327933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 11470347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quintuple buprenorphine dosing (5x daily maintenance dose)
Number of subjects: 14
Study 11470347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sextuple buprenorphine dosing (6x daily maintenance dose)
Number of subjects: 14
Study 11470347 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study 9347651 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ginseng extract 150 mg per capsule, 2 capsules daily for 8 weeks
Number of subjects: 20
Study 9347651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8289001 — intervention group
Group type: EXPERIMENTAL
Intervention: Concho-antropexy
Number of subjects: 25
Study 8289001 — intervention group
Group type: COMPARATOR
Intervention: Total inferior turbinectomy
Number of subjects: 25
Study 3471610 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 8
Study 3471610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30356423 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-layer acupoint PGLA embedding (DAPE)
Number of subjects: 102
Study 30356423 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-layer acupoint PGLA embedding (MAPE)
Number of subjects: 102
Study 30356423 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint embedding (SAE)
Number of subjects: 102
Study 27884916 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 571
Study 27884916 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatments (tranexamic/mefenamic acid, combined oestrogen-progestogen, or progesterone alone)
Number of subjects: 571
Study 24164375 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT group: mailed the FIT, plus educational materials and survey (N = 500)
Number of subjects: 1499
Study 24164375 — intervention group
Group type: COMPARATOR
Intervention: Education only (Ed) group: mailed CRC educational materials and a survey of screening history and preferences (N = 499)
Number of subjects: 1499
Study 24164375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group: received no mailings (N = 500)
Number of subjects: 1499
Study 22682988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training (N=17)
Number of subjects: 44
Study 22682988 — intervention group
Group type: COMPARATOR
Intervention: Active control (TV-watching; N=17)
Number of subjects: 44
Study 22682988 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (N=10)
Number of subjects: 44
Study 21107105 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation
Number of subjects: 312
Study 21107105 — intervention group
Group type: COMPARATOR
Intervention: Hospital intubation
Number of subjects: 312
Study 19082219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nitrous oxide anesthesia (HFA)
Number of subjects: 70
Study 19082219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow nitrous oxide anesthesia (LFA)
Number of subjects: 70
Study 17053895 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether and lumefantrine (AL) treatment
Number of subjects: 13
Study 17053895 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant adults (control group)
Number of subjects: 13
Study 12837873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP) 200 microg/day for 6 weeks
Number of subjects: 65
Study 12837873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) for 6 weeks
Number of subjects: 65
Study 10717490 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT, conjugated equine estrogen 0.625 mg orally daily)
Number of subjects: 40
Study 10717490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily)
Number of subjects: 40
Study 10717490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8856585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulfate (0.04 mg/kg/day, increased by 0.01 mg/kg/day until vomiting ceased)
Number of subjects: 23
Study 8856585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine sulfate (twice the effective intravenous dose) continued for 2 weeks after intravenous treatment
Number of subjects: 23
Study 8856585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography after intravenous atropine treatment
Number of subjects: 23
Study 8856585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulfate
Number of subjects: 23
Study 1738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate plus allopurinol
Number of subjects: 0
Study 1738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol alone
Number of subjects: 0
Study 1738379 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate alone
Number of subjects: 0
Study 1738379 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study 6469181 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 68
Study 6469181 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulphate
Number of subjects: 68
Study 30864528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 80
Study 30864528 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (NADs)
Number of subjects: 80
Study 30864528 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 80
Study 30864528 — intervention group
Group type: EXPERIMENTAL
Intervention: Total health status
Number of subjects: 80
Study 30864528 — intervention group
Group type: EXPERIMENTAL
Intervention: Main groups of NADs
Number of subjects: 80
Study 30848415 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power intervention
Number of subjects: 118
Study 30044293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oral hypoglycemics (OHDs)
Number of subjects: 142
Study 30044293 — intervention group
Group type: COMPARATOR
Intervention: Withholding oral hypoglycemics (OHDs)
Number of subjects: 142
Study 24690440 — intervention group
Group type: EXPERIMENTAL
Intervention: Core vitrectomy additional to three times injections of ranibizumab (3x Rbz)
Number of subjects: 50
Study 24690440 — intervention group
Group type: COMPARATOR
Intervention: 3x Rbz (control)
Number of subjects: 50
Study 22179538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3717
Study 22179538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3717
Study 20104770 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine 10 microg each time (group A)
Number of subjects: 67
Study 20104770 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF 300 microg on the first day, then 10 microg each time for routine immune (group B)
Number of subjects: 67
Study 17502347 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerator-stable formulation of ProQuad
Number of subjects: 1519
Study 17502347 — intervention group
Group type: COMPARATOR
Intervention: Frozen formulation of ProQuad
Number of subjects: 1519
Study 14969836 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MIU daily for 4 weeks, followed by tiw up to 12 months
Number of subjects: 59
Study 14969836 — intervention group
Group type: COMPARATOR
Intervention: IFN 3 MIU daily for 12 weeks, followed by tiw up to 12 months
Number of subjects: 59
Study 11675061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY334370 20 mg
Number of subjects: 99
Study 11675061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY334370 60 mg
Number of subjects: 99
Study 11675061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY334370 200 mg
Number of subjects: 99
Study 11675061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9036906 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction of the tibialis anterior muscle at 25, 50, 75, and 100% of maximum force
Number of subjects: 10
Study 7699639 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program supervised by one instructor once/week for 8 weeks
Number of subjects: 0
Study 7699639 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study 3035849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg bolus followed by 50 micrograms X kg‐1 X h‐1 infusion)
Number of subjects: 9
Study 3035849 — intervention group
Group type: COMPARATOR
Intervention: Control (corresponding volume of preservatives as bolus followed by infusion of diluted preservatives)
Number of subjects: 9
Study 3035849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 9
Study 3035849 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 30194197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114
Study 30194197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-cholecystectomy (MC)
Number of subjects: 114
Study 30194197 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of catalase
Number of subjects: 114
Study 27275798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises training and insertion of a vaginal pessary (pessary group)
Number of subjects: 276
Study 27275798 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises training (control group)
Number of subjects: 276
Study 24091306 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychotherapy (solution-focused or short-term psychodynamic)
Number of subjects: 326
Study 24091306 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326
Study 22118629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 19
Study 22118629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20869680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided ACJ injections
Number of subjects: 20
Study 20869680 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided ACJ injections
Number of subjects: 20
Study 18976393 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant-wise mechanical debridement (QMD)
Number of subjects: 36
Study 18976393 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth mechanical debridement (FMD) with povidone iodine
Number of subjects: 36
Study 18976393 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth mechanical debridement (FMD) with water
Number of subjects: 36
Study 18976393 — intervention group
Group type: COMPARATOR
Intervention: Control group (QMD)
Number of subjects: 36
Study 16184837 — intervention group
Group type: COMPARATOR
Intervention: BAV patients without significant aortic stenosis or regurgitation (n = 10, mean age 27 +/- 8 years)
Number of subjects: 28
Study 16184837 — intervention group
Group type: COMPARATOR
Intervention: BAV patients with moderate or severe aortic regurgitation (n = 18, mean age 32 +/- 9 years)
Number of subjects: 28
Study 12805329 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care with clinical evaluation for ascites and physical performance status, and measurement of serum alpha-fetoprotein (AFP).
Number of subjects: 397
Study 12805329 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group of 324 HCC patients from an Asia-Pacific-wide randomized trial.
Number of subjects: 397
Study 14628189 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 10 mg
Number of subjects: 156
Study 14628189 — intervention group
Group type: COMPARATOR
Intervention: Conventional selegiline tablets 10 mg
Number of subjects: 156
Study 14628189 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 1.25 mg
Number of subjects: 156
Study 10590283 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg/week)
Number of subjects: 0
Study 10590283 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 10590283 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 8829718 — intervention group
Group type: EXPERIMENTAL
Intervention: Original trial medication
Number of subjects: 423
Study 8829718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of psychotropic medication during follow-up
Number of subjects: 423
Study 8829718 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 423
Study 8829718 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe phobic avoidance at baseline
Number of subjects: 423
Study 8829718 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up results
Number of subjects: 423
Study 2090158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak Home Plaque Removal Instrument
Number of subjects: 12
Study 2090158 — intervention group
Group type: COMPARATOR
Intervention: Braun Electric Toothbrush
Number of subjects: 12
Study 386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice a day
Number of subjects: 27
Study 386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg twice a day
Number of subjects: 27
Study 386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 27
Study 386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg twice a day
Number of subjects: 27
Study 386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 160 mg twice a day
Number of subjects: 27
Study 386061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28213385 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 91
Study 28213385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26508370 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 52
Study 26508370 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 52
Study 23394742 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 383
Study 23394742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383